NCT06468683View on ClinicalTrials.gov

F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2027

Conditions

Lupus Erythematosis

Interventions

BIOLOGICAL

After preconditioning with chemotherapy, F01 will be evaluated.

Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)

Trial Locations (1)

200000

Shanghai jiaotong University School of Medicine,Renji Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Simnova Biotechnology Co.,Ltd.

INDUSTRY

NCT06468683 - F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter